Shopping Cart
- Remove All
- Your shopping cart is currently empty
ZLY28 is a novel, first-in-class compound with specific intestinal restriction and oral activity, serving as a dual modulator of FXR and FABP1. Additionally, it is a pioneering anti-NASH agent, utilized in the study of nonalcoholic steatohepatitis (NASH) [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $353 | 35 days | |
5 mg | $1,490 | 35 days |
Description | ZLY28 is a novel, first-in-class compound with specific intestinal restriction and oral activity, serving as a dual modulator of FXR and FABP1. Additionally, it is a pioneering anti-NASH agent, utilized in the study of nonalcoholic steatohepatitis (NASH) [1]. |
In vitro | ZLY28 exhibits suitable hepatic microsomal stability and high target selectivity toward FXR (EC50 = 143 nM) and FABP1 (IC50 = 2.7 μM)[1]. |
In vivo | ZLY28 (oral; 20 mg/kg) significantly improves fatty liver in a NASH mouse model by modulating lipid metabolism, inflammation, oxidative stress, and fibrosis [1]. |
Molecular Weight | 520.4 |
Formula | C29H23Cl2NO4 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.